These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
813 related articles for article (PubMed ID: 24183816)
1. Targeting the ubiquitin proteasome system in haematological malignancies. Crawford LJ; Irvine AE Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816 [TBL] [Abstract][Full Text] [Related]
2. Targeting the ubiquitin+proteasome system in solid tumors. Driscoll JJ; Woodle ES Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552 [TBL] [Abstract][Full Text] [Related]
3. An historic perspective of proteasome inhibition. Esseltine DL; Mulligan G Semin Hematol; 2012 Jul; 49(3):196-206. PubMed ID: 22726542 [TBL] [Abstract][Full Text] [Related]
4. The role of the ubiquitin proteasome system in lymphoma. Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070 [TBL] [Abstract][Full Text] [Related]
5. Proteasome deubiquitinases as novel targets for cancer therapy. D'Arcy P; Linder S Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849 [TBL] [Abstract][Full Text] [Related]
6. Role of the ubiquitin proteasome system in hematologic malignancies. Sahasrabuddhe AA; Elenitoba-Johnson KS Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280 [TBL] [Abstract][Full Text] [Related]
7. The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy. Ao N; Chen Q; Liu G Comb Chem High Throughput Screen; 2017; 20(5):403-413. PubMed ID: 28699494 [TBL] [Abstract][Full Text] [Related]
8. Immunoproteasome Function in Normal and Malignant Hematopoiesis. Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E Cells; 2021 Jun; 10(7):. PubMed ID: 34206607 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954 [TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Park J; Cho J; Song EJ Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies within the ubiquitin proteasome system. Eldridge AG; O'Brien T Cell Death Differ; 2010 Jan; 17(1):4-13. PubMed ID: 19557013 [TBL] [Abstract][Full Text] [Related]
13. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. Chen YJ; Wu H; Shen XZ Cancer Lett; 2016 Sep; 379(2):245-52. PubMed ID: 26193663 [TBL] [Abstract][Full Text] [Related]
14. The immunoproteasome as a target in hematologic malignancies. Kuhn DJ; Orlowski RZ Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549 [TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors: a therapeutic strategy for haematological malignancy. Crawford LJ; Walker B; Irvine AE Front Biosci; 2008 May; 13():4285-96. PubMed ID: 18508511 [TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-proteasome system as a target for anticancer treatment-an update. Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992 [TBL] [Abstract][Full Text] [Related]
19. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy. Driscoll JJ; Dechowdhury R Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340 [TBL] [Abstract][Full Text] [Related]
20. The immunoproteasome as a therapeutic target for hematological malignancies. Miller Z; Lee W; Kim KB Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]